



# GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557

E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

---

13.02.2023

To,  
The Manger [Listing]  
The BSE Limited  
The Secretary, Listing Department  
Phirozejeeebhoy Towers,  
Dalal Street, Fort,  
Mumbai- 400001  
Scrip code: 530317

Dear Sirs/Madam,

**Sub: Submission of Un-Audited Financial Results of the Company and Limited Review Report as per the provisions of Regulation 33 of SEBI (LODR) Regulations, 2015**

Please find the enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

1. Un-audited Financial Results of the Company for the quarter ended 31<sup>st</sup> December, 2023.
2. A certified copy of Limited Review Report on standalone financials for the quarter ended 31<sup>st</sup> December, 2023 given by the statutory auditors.

These are also being made available on the website of the Company at [www.godavaridrugs.com](http://www.godavaridrugs.com).

The Board Meeting Commenced at 04:30 P.M and concluded at 05:30 PM

Please take the above in your records.

**Thanking You,**  
*For Godavari Drugs Limited*

**Venkaresh Achanta**  
**Company Secretary & Compliance Officer**

**GODAVARI DRUGS LIMITED**  
CIN NO.L24230TG1987PLC008016  
Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023**

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Nine Months ended on			Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	30.09.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	4311.05	3954.25	3915.81	11807.18	7496.13	12225.51	15962.48
2	Other Income	5.02	0.35	29.86	50.58	45.56	49.73	65.53
3	<b>Total Revenue from operations (1+2)</b>	<b>4316.07</b>	<b>3954.60</b>	<b>3945.67</b>	<b>11857.76</b>	<b>7541.69</b>	<b>12275.24</b>	<b>16028.01</b>
4	<b>Expenses</b>							
	(a) Cost of materials consumed	3294.56	3035.42	2735.08	8,974.32	5,679.76	10286.77	13782.07
	Changes in inventories of finished goods & work-in-progress	138.02	40.27	475.32	340.62	202.60	-362.92	-976.30
	(b)							
	(c) Employee benefits expense	127.30	119.06	119.69	368.31	241.01	350.40	484.04
	(d) Depreciation & amortization expense	49.54	49.38	51.42	146.30	96.76	144.77	194.35
	(e) Finance Costs	127.48	129.81	109.92	368.27	240.79	289.79	392.73
	(f) Other Expenses	399.22	453.23	358.80	1240.84	841.62	1227.42	1680.59
	<b>Total expenses</b>	<b>4136.12</b>	<b>3827.17</b>	<b>3850.23</b>	<b>11438.66</b>	<b>7302.54</b>	<b>11936.23</b>	<b>15557.48</b>
5	<b>Profit before exceptional Items and tax</b>	<b>179.95</b>	<b>127.43</b>	<b>95.44</b>	<b>419.10</b>	<b>239.15</b>	<b>339.01</b>	<b>470.53</b>
6	Exceptional items	-5.83	-	-	-5.83	-	-	22.95
7	<b>Profit before Tax (5-6)</b>	<b>174.12</b>	<b>127.43</b>	<b>95.44</b>	<b>413.27</b>	<b>239.15</b>	<b>339.01</b>	<b>493.48</b>
8	Tax expense	-52.03	-41.85	-28.53	-124.56	-72.53	-93.56	-114.89
9	<b>Net Profit for the period (7-8)</b>	<b>122.09</b>	<b>85.58</b>	<b>66.91</b>	<b>288.71</b>	<b>166.62</b>	<b>245.45</b>	<b>378.58</b>
10	<b>Other Comprehensive Income</b>							
	(i) Items that will not be reclassified to profit or loss							
	(ii) Income tax relating to Items that will not be reclassified to profit or loss							
	(iii) Items that will be reclassified to profit or loss							
	(iv) Income tax relating to Items that will be reclassified to profit or loss							
11	<b>Total Comprehensive Income (9+10)</b>	<b>122.09</b>	<b>85.58</b>	<b>66.91</b>	<b>288.71</b>	<b>166.62</b>	<b>245.45</b>	<b>378.58</b>
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity(Reserves and Surplus)							2588.67
14	<b>Earnings per share (of Rs.10/- each ) (not annualized)</b>							
	(a) Basic	1.62	1.14	0.89	3.83	2.21	3.26	5.03
	(b) Diluted	1.62	1.14	0.89	3.83	2.21	3.26	5.03

1.The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 13.02.2024

2.The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable

3.The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.

4.Corresponding figures in previous year / period have been regrouped wherever considered necessary.



For GODAVARI DRUGS LIMITED  
*[Signature]*  
Mohit Jaju  
Whole Time Director & CFO  
DIN: 03405414

Place: Secunderabad  
Date: 13.02.2024

**Independent Auditor's Review Report on unaudited quarterly financial results of  
Godavari Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing  
Obligations and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors  
Godavari Drugs Limited  
Hyderabad

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and nine months ending on December 31, 2023 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,  
Chartered Accountants  
FRN: 00278S



Ayyadevara Srinivas  
Proprietor  
ICAI Membership No. 028803  
Hyderabad Feb 13, 2024.  
UDIN: 24028803BKHJGP5600

